<DOC>
	<DOCNO>NCT00293111</DOCNO>
	<brief_summary>An Open Label , Multi-Center , Phase II Study Investigate Safety Efficacy SDX-101 ( R-Etodolac ) Patients Relapsed Refractory Multiple Myeloma ( MM )</brief_summary>
	<brief_title>Safety Efficacy SDX-101 ( R-Etodolac ) Patients With Relapsed Refractory Multiple Myeloma ( MM )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Etodolac</mesh_term>
	<criteria>1 . Previously diagnosis multiple myeloma determine two major criterion , major criterion 1 plus minor criterion b , c , , major criterion 3 plus minor criterion c , minor criterion , b c , b , d. Major criterion : Plasmacytomas tissue biopsy Bone marrow plasmacytoma ( &gt; 30 % plasma cell ) Monoclonal immunoglobulin spike serum electrophoresis immunoglobulin G ( IgG ) &gt; 3.5 g/dl immunoglobulin A ( IGA ) &gt; 2.0 g/dl ; kappa lambda light chain excretion &gt; 1 g/day 24 hour urine protein electrophoresis Minor criterion : 1 . Bone marrow plasmacytoma ( 10 30 % plasma cell ) 2 . Monoclonal immunoglobulin present less magnitude give major criterion 3 . Lytic bone lesion 4 . Normal IgM &lt; 50 mg/dl , IgA &lt; 100 mg/dl , IgG &lt; 600 mg/dl 2 . Has relapse refractory disease determine follow : Relapsed disease : • Disease progression develop follow achievement least stable disease well antimyeloma regimen . Refractory disease : • Disease progression develop therapy antimyeloma regimen prior achievement least stable disease well . Includes development disease progression maintenance consolidation therapy glucocorticoid cytotoxic chemotherapy . 3 . Age &gt; 18 signing inform consent . 4 . ECOG performance status 02 . 5 . Renal function 1.5 x upper limit normal ( blood urea nitrogen [ BUN ] , serum creatinine 6 . Liver function ≤ 1.5 time upper limit normal ( total bilirubin , SGOT ( AST ) SGPT ( ALT ) value ) . 7 . Female patient childbearing potential must negative pregnancy test ( serum human chorionic gonadotropin , HCG ) ; men woman reproductive potential must employ effective contraceptive method study therapy , 1 month follow completion treatment . 8 . Signed IRBapproved informed consent patient prior study related procedure . 1 . History prior malignancy last 3 year exception resect basal cell carcinoma , situ cervical cancer time resect malignancy evidence recurrence 5 year since diagnosis . 2 . Patients hemoglobin count &lt; 8.0 g/dl , platelet count &lt; 50,000 cells/mm3 , absolute neutrophil count ( ANC ) &lt; 1000 cells/mm3 . 3 . Serious infection , medical condition , psychiatric condition , opinion investigator , place subject unacceptable risk might interfere achievement study objective . 4 . Chronic viral infection : positive hepatitis B hepatitis C serology , know positive human immunodeficiency virus ( HIV ) human Tleukemia/lymphoma virus ( HTLV ) . 5 . Peptic ulcer disease ( PUD ) require treatment surgical intervention within last 2 year . 6 . The use steroids chronic nonsteroidal antiinflammatory drug 28 day prior initiation study medication . 7 . Treatment chemotherapy treatment multiple myeloma investigational agent within 6 week study entry . 8 . History allergy NSAIDs aspirininduced asthma . 9 . Pregnancy currently breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
</DOC>